Get the Stockscreener App
9.22
3.28%
0.38
Organon Co stock is traded at $9.22, with a volume of 238.33K.
It is up +3.28% in the last 24 hours and up +51.41% over the past month.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
See More
Previous Close:
$8.84
Open:
$8.97
24h Volume:
238.33K
Relative Volume:
0.04
Market Cap:
$2.40B
Revenue:
$6.22B
Net Income/Loss:
$187.00M
P/E Ratio:
12.87
EPS:
0.7166
Net Cash Flow:
$508.00M
1W Performance:
-0.87%
1M Performance:
+51.41%
6M Performance:
+2.13%
1Y Performance:
-18.77%
1-Day Range:
$8.9137
$9.23
1-Week Range:
$8.785
$9.83
52-Week Range:
$5.69
$13.24
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
9.23 | 2.30B | 6.22B | 187.00M | 508.00M | 0.7166 |
LLY
Lilly Eli Co
|
920.20 | 806.72B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.28 | 544.73B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
205.35 | 362.81B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
196.24 | 303.62B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
147.99 | 282.35B | 54.72B | 14.02B | 15.32B | 7.1855 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN
What does Sun Pharma gain from its $12-billion Organon bid? - MSN
Organon (OGN) Is Up 8.4% After VTAMA Wins Key Steroid-Free Role In New Pediatric Guidelines - simplywall.st
Why Organon (OGN) Drew Buyout Buzz After a Sharp Repricing - Yahoo Finance
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility - MSN
Organon & Co (OGN) Stock Price Quote Today & Current Price Chart - Capital.com
Organon rises as Sun Pharma said to near $12B buyout deal - MSN
This women’s health company is drawing takeover interest. The stock is soaring. - MSN
Notable healthcare headlines for the week: J&J, Abbott and Organon in focus - MSN
Organon & Co. Soars 17.92% to Hit Intraday High of USD 6.96 - Markets Mojo
Organon gains as Sun Pharma, Grünenthal said to seek takeover deals - MSN
Organon (OGN) stock drops despite market gains: Important facts to note - MSN
Sun Pharma preps for Organon bid - ifr-logo
Healthcare Sector Analysis: Organon & Co. (OGN) Leads with Low F - GuruFocus
Organon (OGN) rises higher than market: Key facts - MSN
Organon (OGN) Rises Higher Than Market: Key Facts - Yahoo Finance
Organon (OGN) Shares Rise as Sun Pharma and Grünenthal Eye Acqui - GuruFocus
Organon & Co. (OGN) Stock Rises 4% to $9.6 - AlphaStreet
Organon & Co. (NYSE:OGN) Shares Gap UpTime to Buy? - MarketBeat
Organon gets buyout interest from Sun Pharma, Grünenthal (OGN) - Seeking Alpha
Press Release: Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026 - 富途牛牛
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026 - Bluefield Daily Telegraph
Organon & Co. (NYSE:OGN) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
Why Organon (OGN) Is Surging as Buyout Interest Gains Traction - Insider Monkey
Sun Pharma, Grünenthal Are Said to Vie for US-Listed Organon - Bloomberg
AAD recommends Organon’s VTAMA cream for pediatric atopic dermatitis - Investing.com
Only steroid-free cream AAD backs for all child eczema severities - Stock Titan
Massachusetts Financial Services Co. MA Cuts Stock Holdings in Organon & Co. $OGN - MarketBeat
Sun Pharma Faces Fresh Organon Acquisition Reports After Official Denial - scanx.trade
Organon & Co. Experiences Evaluation Revision Amidst Mixed Market Indicators and Volatility - Markets Mojo
Organon (OGN) climbs 39% on $12-billion merger buzz - MSN
Organon & Co. (NYSE:OGN) Q4 2025 earnings call transcript - MSN
Organon & Co. Shares Drop 6.4% as Analysts Forecast Weak Growth - National Today
Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
3 Reasons to Avoid OGN and 1 Stock to Buy Instead - Yahoo Finance UK
Organon & Co. (NYSE:OGN) Shares Down 6.4%Time to Sell? - MarketBeat
Unusually active option classes on open April 13th - TipRanks
Organon Takeover At $15? Probably Not, Here's Why (NYSE:OGN) - Seeking Alpha
Organon Stock Skyrockets 28% Following Reports of $12 Billion Buyout Offer From Sun Pharma - TIKR.com
Sun Pharma’s Reported US$12b Bid Recasts Organon’s Risk Reward Profile - Sahm
American pharmaceutical MSD receiving billions in tax benefits in the Netherlands - NL Times
EBIT per share of Organon & Co. – SWB:7XP - TradingView — Track All Markets
Is Organon (OGN) Now An Opportunity After Its Recent Share Price Surge? - Yahoo Finance
Buy or Sell Organon Stock in 2026? Takeover Buzz Lifts Shares 28% as Analysts Stay Cautious - International Business Times Australia
Institutional Money Floods Organon as Analysts Warn and Charts Conflicted - Bitget
Organon (OGN) Climbs 39% on $12-Billion Merger Buzz - Insider Monkey
Key deals this week: Organon, UMG, Whitestone REIT, Gilead and more - Seeking Alpha
Avoiding Lag: Real-Time Signals in (OGN) Movement - Stock Traders Daily
Organon Shares Soar as Sun Pharmaceutical Eyes $12B Deal - timothysykes.com
Morning Movers: Organon jumps after report of Sun Pharmaceutical bid - Yahoo Finance
Morgan Stanley Reaffirms Their Hold Rating on Organon (OGN) - The Globe and Mail
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):